Stocks of ATAI Life Sciences N.V (NASDAQ:ATAI) traded higher last session on Wall Street, up 1.48% to $2.75.
ATAI stock price is now 40.46% away from the 50-day moving average and 73.38% away from the 200-day moving average. The market capitalization of the company currently stands at $552.07M.
With the price target reduced from $15 to $10, H.C. Wainwright maintained Buy rating for ATAI Life Sciences N.V (NASDAQ: ATAI). On April 03, 2024, Maxim Group Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock keeping its target price maintained at $6, while ‘Loop Capital’ rates the stock as ‘Buy’
In other news, SAHIL KIRPEKAR, Officer bought 83,332 shares of the company’s stock on Jul 02 ’25. The stock was bought for $233,830 at an average price of $2.81. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 01 ’25, Officer SAHIL KIRPEKAR bought 106,093 shares of the business’s stock. A total of $294,381 was incurred on buying the stock at an average price of $2.77. A total of 31.72% of the company’s stock is owned by insiders.
During the past 12 months, ATAI Life Sciences N.V has had a low of $1.03 and a high of $2.89. As of last week, the company has a debt-to-equity ratio of 0.19, a current ratio of 4.07, and a quick ratio of 4.07.
The net profit margin was -38852.87% and return on equity was -62.43% for ATAI.
